Head-To-Head Analysis: Tilray Brands (NASDAQ:TLRY) & TherapeuticsMD (NASDAQ:TXMD)

Tilray Brands (NASDAQ:TLRY) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Institutional and Insider Ownership

9.3% of Tilray Brands shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 1.6% of Tilray Brands shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Tilray Brands and TherapeuticsMD”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45 million	0.55	-$121.40 million	($1.08)	-3.44
TherapeuticsMD	$3.02 million	7.66	-$570,000.00	$0.02	100.00

TherapeuticsMD has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tilray Brands and TherapeuticsMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Analyst Ratings

This is a summary of recent ratings for Tilray Brands and TherapeuticsMD, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2	2	3	1	2.38
TherapeuticsMD	1	0	0	0	1.00

Tilray Brands currently has a consensus price target of $6.38, indicating a potential upside of 71.83%. Given Tilray Brands’ stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than TherapeuticsMD.

Risk & Volatility

Tilray Brands has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Summary

TherapeuticsMD beats Tilray Brands on 9 of the 15 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.